ArticleRegenerative biomaterials2026
Biomimetic lung-targeting vehicle coupled with cryo-shocked leukocyte and inflammation-anchored liposome for drug delivery and anti-inflammation in treatment of acute pneumonia.
Article in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pneumonia is a severe pulmonary inflammation, and it is critical to promptly suppress the dysregulated inflammatory responses to prevent mortality. Glucocorticoids are the first-line therapeutic drugs but with poor tissue selectivity and dose-dependent adverse effects. In this work, cryo-leukocyte, an autologous cell-derived immunosuppressor, was created by leveraging the cryo-shocking technology by the quick shock of normal leukocytes with liquid nitrogen. After coupling with aICAM-1 functionalized liposomes, this micro/nano composite system could achieve efficient and prompt inflammation alleviation in acute pneumonia. The engineered cryo-leukocytes were of well biocompatibility after evaluation of blood toxicity, tissue toxicity, acute toxicity and long-term biosafety for over 6 months, etc. Cryo-leukocytes preserved similar cellular receptors as normal leukocytes, capable of recognizing and binding inflammatory cytokines but without activation of immune cascade, thus exhibiting obvious anti-inflammation efficacy by acting as 'mixed cytokines antibodies'. The immunosuppression efficacy of cryo-leukocytes was also superior than that of its sub-group cells of cryo-neutrophil, cryo-monocyte and cryo-lymphocyte, due to relative wide protein expressions that are related to the immune responses. Besides, cryo-leukocytes coupled with aICAM-1 functionalized liposome exhibited obvious anchoring effect in inflammation sites by the interaction of ICAM-1 antibody and ICAM-1 molecules that were over-expressed on inflammatory pulmonary endothelial cells, thus served as superior drug lung-targeting vehicle to maximally enhance the accumulation of traditional Chinese and Western medicines in the lungs. A total of 68.1% of drug signals could be observed in lung tissues compared with other major organs after intravenous injection, significantly higher than that of micro-sized drug-loaded cryo-leukocyte (18.6%) and nano-sized drug-loaded aICAM-1-liposome (12.2%). In a lipopolysaccharide-induced acute pneumonia mice model, the drug-loaded cryo-leukocyte achieved superior anti-inflammation efficacy with 87.5% survival of mice after treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.